

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-42. (canceled)
43. (previously amended) A humanized catalytic antibody capable of degrading cocaine comprising a light chain wherein the amino acid sequence of complementarity determining region 1 is RSSXGTITXXNYAN (Seq ID NO: 73), the amino acid sequence of complementarity determining region 2 is XNNYRPP (Seq ID NO: 74) and the amino acid sequence of complementarity determining region 3 is ALWYSNHWV (Seq ID NO: 75) and a heavy chain wherein the amino acid sequence of complementarity determining region 1 is DYNMY (Seq ID NO: 76), the amino acid sequence of complementarity determining region 2 is YIDPXNGXXFYNQKFXG (Seq ID NO. 77) and the amino acid sequence of complementarity determining region 3 is GGGLFAX (Seq ID NO: 78).
44. (previously amended) A humanized polypeptide comprising a light chain domain which comprises a complementarity determining region 1 having the amino acid sequence RSSXGTITXXNYAN (Seq ID NO: 73), a complementarity determining region 2 having the amino acid sequence XNNYRPP (Seq ID NO: 74) and a complementarity determining region 3 having the amino acid sequence ALWYSNHWV (Seq ID NO: 75), interposed between appropriate framework regions, and linked to said light chain domain a heavy chain domain which comprises a complementarity determining region 1 having the amino acid sequence DYNMY (Seq ID NO: 76), a complementarity determining region 2 having the amino acid sequence YIDPXNGXIFYNQKFXG (Seq ID NO: 77) and a complementarity determining region 3 having the amino acid sequence GGGLFAX (Seq ID NO: 78) interposed between appropriate framework regions, said

polypeptide having a conformation suitable for degrading cocaine.

45. (currently amended) A pharmaceutical composition for decreasing the concentration of cocaine in a subject which comprises an amount of the antibody of ~~claim 41~~ claim 43 effective to degrade cocaine in the subject and a pharmaceutically acceptable carrier.
46. (currently amended) A method of decreasing the concentration of cocaine in a subject which comprises administering to the subject an amount of the antibody of ~~claim 41~~ claim 43 effective to degrade cocaine in the subject, so as to thereby decrease the concentration of cocaine in the subject.
47. (currently amended) A pharmaceutical composition for treating cocaine overdose in a subject which comprises an amount of the antibody of ~~claim 41~~ claim 43 effective to degrade cocaine in the subject and a pharmaceutically acceptable carrier.
48. (currently amended) A method for treating cocaine overdose in a subject which comprises administering to the subject an amount of the antibody of ~~claim 41~~ claim 43 effective to degrade cocaine, so as to thereby treat cocaine overdose in the subject.
49. (New) A pharmaceutical composition for decreasing the concentration of cocaine in a subject which comprises an amount of the antibody of claim 44 effective to degrade cocaine in the subject and a pharmaceutically acceptable carrier.
50. (New) A method of decreasing the concentration of cocaine in a subject which comprises administering to the subject an amount of the antibody of claim 44 effective to degrade cocaine in the subject, so as to thereby decrease the concentration of cocaine in the subject.

51. (New) A pharmaceutical composition for treating cocaine overdose in a subject which comprises an amount of the antibody of claim 44 effective to degrade cocaine in the subject and a pharmaceutically acceptable carrier.
52. (New) A method for treating cocaine overdose in a subject which comprises administering to the subject an amount of the antibody of claim 44 effective to degrade cocaine, so as to thereby treat cocaine overdose in the subject.